Recent findings that human serum contains stably expressed microRNA (miRNA) have revealed a great potential of serum miRNA signature as disease fingerprints to predict survival. We used genome-wide serum miRNA expression analysis to investigate the role of serum miRNA in predicting prognosis of non-small-cell lung cancer (NSCLC).
INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide, and approximately 80% of the patients have non-small-cell lung cancer (NSCLC). Because lung cancer is a deadly disease that has a 5-year survival rate of less than 15%, prognostic assessment of the patient is essential for the choice of better therapeutic strategies. One of the major clinical determinants in NSCLC prognosis is tumor extension, roughly characterized by the stage. However, a large variability in disease outcome has been observed for a subset of patients with the same clinical features, and the current staging systems are inadequate to predict the treatment outcome of NSCLC.
It has been suggested that discovery and application of molecular biomarkers that incorporate with traditional cancer staging and prognosis signature could improve the management of patients with NSCLC. 1 Advances in genomics and proteomics have generated many new candidate markers with potential clinical values, particularly the gene-expression profiling by microarray or realtime reverse transcriptase polymerase chain reaction (RT-PCR). [2] [3] [4] Recently, the discovery of microRNAs (miRNAs) has opened new avenues for cancer diagnosis and prediction of treatment response. [5] [6] miRNAs are an abundant class of small, nonprotein-coding RNAs that function as negative gene regulators.
7-8 Because a single miRNA can regulate hundreds of downstream genes with different biologic entities, the information gained from miRNA profiling may provide more accurate classification of cancer subtypes than the use of expression profiles of protein-coding genes. 6, 9 In lung cancer, it has been shown that miRNA expression profiles and specific miRNAs in lung tissue are correlated with disease prognosis and clinical outcome. 10, 11 Recently, we discovered with excitement that human serum/ plasma contains a large amount of stable miRNAs and that unique expression patterns of serum miRNAs under a specific disease condition imply a great potential of serum miRNA profiling as the fingerprint for diseases. 12 Consistently, other studies also have suggested that serum miRNAs are novel noninvasive biomarkers for cancers. [13] [14] [15] In this study, we hypothesize that there is a serum miRNA profile that can be used as a fingerprint to predict clinical outcome of NSCLC. To address this hypothesis, we screened serum miRNAs by using Solexa sequencing followed by an extensively self-validated study that uses individual quantitative RT-PCR (qRT-PCR) assays in a cohort of 303 patients with stages I to IIIa NSCLC.
PATIENTS AND METHODS
Detailed patients recruitment and methodologic issues are described in the Appendix (online only). Patient characteristics and clinical features were partly described previously. 16 To control disease heterogeneity, only patients with stages I to IIIa lung cancer with adenocarcinoma and squamous cell carcinoma treated with both surgical operation and adjuvant chemotherapies were included on this study. Overall, 303 patients who met all criteria and had completed follow-up and clinical information were included in this analysis. Among them, 60 patients were selected for the discovery stage for Solexa sequencing of serum miRNAs, 30 patients who survived more than 30 months (average, 49.54 months; range, 34.6 to 61.8 months) on the last follow-up were classified as the longer-survival group, whereas 30 patients who had survival times less than 25 months (average, 9.54 months; range, 2.0 to 22.5 months) were classified as the shorter-survival group. The remaining 243 patients with NSCLC were randomly classified as either training (n ϭ 120) or testing (n ϭ 123) sets by using computer-generated random numbers.
RNA isolation, Solexa sequencing, and qRT-PCR assay were described previously.
12 In each step from serum purification to qRT-PCR, an equal volume of serum was processed. Because there was no consensus on the use of housekeeping miRNA for serum qRT-PCR analysis, miRNA expression levels all were controlled with a healthy donor sample. For reverse transcription, the same control sample was processed together with the testing samples according to their plate formats. In each 96-well plate, the control sample was assayed in sextuple in parallel with other patient samples, and the ratios of serum miRNAs were calculated by using the equation 2 -‚CT , in which ‚CT ϭ cycle threshold (CT) patient -CT control . In this study, the coefficient of variation (CV) of CT values for the control sample between different plates for different miRNAs was small and comparable (CV ϭ 0.021 for miR-486, 0.061 for miR-30d; CV ϭ 0.047 for miR-1 and 0.041 for miR-499), which indicated that the reverse transcription and quantitative PCR were comparably efficient in all reactions.
The associations between overall survival and serum miRNA expression levels were estimated by using the Kaplan-Meier method, log-rank test, and Cox proportional hazard regression models. We assigned each patient a risk score according to a linear combination of the expression level of the miRNA, weighted by the regression coefficient from the training samples. 2, 11, 17 The risk score was calculated as follows: risk-score ϭ (0.969 ϫ expression level of miR-486) ϩ (0.973 ϫ expression level of miR-30d) ϩ (Ϫ0.650 ϫ expression level of miR-1) ϩ (Ϫ0.815 ϫ expression level of miR-499). The Cox stepwise regression model and stratification analyses also were conducted. All the statistical analyses were performed with Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC).
RESULTS

Detection of Serum miRNAs and Their Associations With Survival of Patients With NSCLC
As shown in Appendix Table A2 (online only), the 30 patients in the longer-survival group and the 30 patients in the shorter-survival group in the discovery stage were exactly matched on stage and smoking status, and the frequencies of histologic type, age, and sex were not significantly different between the two groups. Overall, 109 miRNAs were detected by Solexa sequencing from the longer-survival group, whereas 101 were detected from the shorter-survival group. We selected miRNAs that satisfied two criteria for additional qRT-PCR validation: having at least 50 copies in either longer-survival or shorter-survival groups; and showing five-fold altered expression between the two pooled samples. As a result, 11 serum miRNAs were identified and subjected to additional analyses (Table 1 ). In addition, two let-7 family members (ie, let-7a and let-7g) with two-fold expression changes between the two groups were included also, because their expressions in tissue specimen were reported to be correlated with lung cancer survival. 18, 19 We then performed individual qRT-PCR assay to quantify each of the identified miRNAs. As shown in Table 1 , the levels of four miRNAs (ie, miR-486, miR-30d, miR-1 and miR-499) were significantly different between the longer-survival and shorter-survival groups (P Ͻ .001 for miR-486; Ͻ .001 for miR-30d; .001 for miR-1; and Ͻ .001 for miR-499).
Hazard ratios (HRs) from the Cox regression analysis showed that the expression levels of the four miRNAs were significantly associated with cancer death in a dose-dependent manner (for trend ϭ .001 for miR-486, Ͻ .001 for miR-30d, .003 for miR-1, and Ͻ .001 for miR-499). The difference in the median survival time (MST) of lung cancer between different expression levels of the four miRNAs in quartiles were all statistically significant (log-rank test P ϭ .009 for miR-486, Ͻ .001 for miR-30d, Ͻ .001 for miR-1, and .001 for miR-499; Appendix Table A3 , online only).
Association Between the Expression of the Four miRNAs in Serum and Patient Survival
We additionally tested the predictive effects of the four miRNAs on lung cancer survival among 243 patients with NSCLC, randomly grouped into one training data set and one testing data set (Appendix Table A2 ). From the training set, high serum expression levels of miR-486 (median, 0.795) and miR-30d (median, 0.680), and low serum expression levels of miR-1 (median, 0.675), miR-499 (median, 0.750) were all individually associated with unfavorable survival (Appendix Table A4 and Fig A1A, online only). When these threshold values were applied to the testing set, comparable log-rank P values and HRs, respectively, also were observed (Appendix Table A4 and Fig  A1B) . We then took the four miRNAs into simultaneous consideration and found that patients carrying two or more high-risk miRNAs had significantly increased probability of shortened survival than those carrying zero or one high-risk miRNA in both the training and testing sets (Appendix Table A4 and Figs A1A, A1B).
Results for all the 303 patient samples, including the discovery data set, also were similar to those from the training set. As listed in Table 2 , patients with high serum expression levels of risk miRNAs and low serum expression levels of protective miRNAs had significantly lower MSTs (31.30 months for miR-486, 22.37 months for miR-30d, 22.87 months for miR-1, and 23.73 months for miR-499; all v not reached; Appendix Fig A1C) . In the combined analysis, we found that patients carrying two or more high-risk miRNAs had significantly increased probability of cancer death in a dosedependent manner (log-rank test Ͻ .0001; HR ϭ 3.14; 95% CI, 1.65 to 5.97 for two high-risk miRNAs carriers; HR, 16.52; 95% CI, 8.62 to 31.68 for 3 high-risk miRNAs carriers; and HR, 34.13; 95% CI, 16.28 to 71.56 for four high-risk miRNAs carriers; Table 2 ) compared with those carrying zero or one high-risk miRNA.
Serum Four-miRNA Signature and Patient Survival
We then used the four miRNAs to construct a signature by a risk-score method. The patients in the training set were ranked according to their risk scores and divided into high-risk or low-risk groups by using the median risk score as the cutoff point (Table 3) . Patients with a high-risk four-miRNA signature had significantly shortened MST (20.30 months v not reached; P Ͻ .001) and a 10.74-fold increased HR (95% CI, 4.28 to 26.96) for cancer death. The same risk-score formula and cutoff point obtained from the training set were directly applied to the 123 patients in the testing set and to the all-combined 303 patients. Similar to the findings from the training set, patients with a high-risk miRNA signature had significantly shortened MST than patients with a low-risk miRNA signature (23.97 v 43.17 months; P Ͻ .001 for the testing set; and 18.43 months v not reached; P Ͻ .001 for the all-combined 303 patients) and elevated HR (HR, 6.35; 95% CI, 3.07 to 13.15 for the testing set; and HR, 9.31; 95% CI, 5.78 to 14.98 for the all-combined 303 patients). To test the stability of the cutoff point, we also performed 1,000 times of cross-validations. Each time, we generated a risk-score formula on 120 randomly selected participants from the training and testing sets. The average and standard deviation of the 1,000 threshold values were 0.455 Ϯ 0.578. On the basis of these cutoff points, the all-combined 303 patients were classified into high-risk or low-risk groups. The mean with an empirical standard error of the 1,000 HRs was 8.29 Ϯ 1.84, and the empiric 95% CI was between 4.48 and 10.59.
We showed the distribution of serum miRNA expression levels, patient risk scores, and survival time of the all-combined 303 patients in Fig 1. Patients with high-risk scores tended to have high-risk miRNAs, whereas patients with low-risk scores tended to have more protective miRNAs. Patients with high-risk scores died sooner than those with low-risk scores.
Serum miRNA Signatures and Patient Survival Independent From Stage and Histology
To investigate whether the miRNA signatures could distinguish high-risk versus low-risk groups of patients by stage (ie, NSCLC stage I, II, or IIIa) and histology subtypes (ie, adenocarcinoma or squamous cell carcinoma), we performed stratified analyses. We found that the increased risk of cancer death associated with the high-risk fourmiRNA signature was comparable among patients with stage I (HR, 12.79; 95% CI, 4.67 to 35.03), II (HR, 9.38; 95% CI, 3.00 to 29.36), and IIIa (HR, 8.99; 95% CI, 4.75 to 17.03) carcinomas and between patients with adenocarcinoma (HR, 9.34; 95% CI, 5.12 to 17.04) and squamous cell carcinoma (HR, 12.11; 95% CI, 4.86 to 30.17). We also performed stepwise Cox proportional hazards analyses with selected demographic characteristics, clinical features, and the four miRNAs or the four-miRNA signature. The four miRNAs or the four-miRNA signature, together with stage remained in the regression model with a significance level of .05 for entering and .10 for removing of the variables (P all Ͻ .001), suggesting that either four miRNAs individually or the four-miRNA signature as a group may be used as biomarkers to predict the lung cancer survival in this study population (Appendix Table A5 , online only).
DISCUSSION
NSCLC is a heterogeneous disease. The current standard of treatment for patients with stage Ia NSCLC is surgical resection, but a subgroup of these patients might benefit from adjuvant chemotherapy; in contrast, patients with clinical stages Ib to IIIa NSCLC receive both operation and adjuvant chemotherapy, of whom some may receive potentially toxic chemotherapy unnecessarily. [20] [21] [22] Staging systems for lung cancer may have reached their limit of usefulness for predicting outcomes, and molecular biomarkers add values.
2,4,23-27 Thus, the ability to identify subgroups of patients more accurately, may refine the prognostic model and lead to more personalized cancer treatment. In this study of lung cancer survival in Chinese, we found that the four-miRNA signature (ie, miR-486, miR-30d, miR-1 and miR-499) derived from a genome-wide serum miRNA expression profiling were significantly associated with overall survival of lung cancer, which may serve as a noninvasive predictor for prognosis of NSCLC. These serum markers, if validated in other populations and in prospective studies, will provide the opportunity for a randomized clinical trial to evaluate the benefit of identifying subgroups of patients with NSCLC who are at high risk of unfavorable survival. In addition, because of noninvasive characteristics of these serum markers and easy detection in clinical settings, such kind of miRNA signatures may be used to additionally investigate drug response and chemosensitivity of NSCLC by observing their dynamic expression levels and profiles before and after treatment.
Recent studies by both us and others implied that the unique patterns of serum miRNAs may serve as noninvasive biomarkers for cancer development and prognosis.
12-15,28 Therefore, determination of miRNA signatures in patients by using qRT-PCR to assess the profile of a small number of miRNAs as shown in this study is a clinically applicable procedure. Endogenous circulating miRNAs are stable, are well protected from RNases, and remain stable even after being subjected to harsh conditions. 12,15 Because of the simplicity and reproducibility of getting a blood sample, easily testable biomarkers found in blood serum may have a great potential in surveillance of cancer outcomes.
The source of serum miRNAs and, more importantly, the mechanisms that control the generation of serum miRNAs remain enigmatic. We have detected almost identical miRNA profilings in serum and blood cells from healthy individuals. 12 However, under the disease condition like cancer, miRNAs entered circulation dominantly from tumor cells.
12, 15 The release mechanisms may be complicated and may involve tumor-derived microvesicles/exosomes. 29, 30 Microvesicles are 30 to 100 nm in diameter and are shed from many different cell types under both normal and pathologic conditions.
31
They can transfer some of their contents (ie, proteins, mRNAs, and miRNAs) to other cell types and generate similar functional significance. 29, 30, 32, 33 It was shown that some of the miRNAs were expressed at higher levels in microvesicles shed from tumor cells than inside the cells, which implies that these miRNAs may be selectively enriched in microvesicles. 30 For lung cancer, the let-7 miRNA family was the only one in tissue specimen that was consistently reported to be associated with clinical outcome.
10,11,19 However, it is not the case in the serum we tested in this study. Several suggested predictors (ie, miRNAs) from tissue specimen, like miR-20, miR-106a, miR-17-3p, miR-155, miR-145, miR-93, 10 miR-137, miR-372, and miR-182-3p 11 were not detectable by Solexa sequencing in the serum. Therefore, the predictive role of serum miRNAs could be independent from tissue specimen. In this study, clear and significant associations between noninvasive miRNA signatures from serum and lung cancer prognosis are potentially useful in clinical practice, although the mechanisms need to be additional explored.
Our understanding of miRNA expression patterns as potential biomarkers for diagnosis, prognosis, personalized therapy, and disease management is still in its infancy. A full understanding of the mRNA targets and the molecular mechanisms by which the miRNAs regulate NSCLC survival may lead to clinical application of serum miRNAs. Among the four miRNAs, only miR-1 was extensively evaluated in the context of lung cancer in the literature. MiR-1 was reported to be significantly reduced in primary lung cancer tissue and cell lines because of both genetic and epigenetic alterations. 34 Ectopic expression of miR-1 significantly reduced A549 lung cancer cell proliferation, cell migration and motility, and tumor growth in nude mice, whereas depletion of miR-1 facilitated lung cancer cell (N417) growth. 34 The downregulation of MET oncogene could be a possible mechanism by which miR-1 regulates growth and metastatic potential of these cells. 34, 35 Furthermore, trichostatin A, a histone deacetylase (HDAC) inhibitor, can activate the repressed miR-1 in lung cancer cells, whereas HDACs have been identified as therapeutic targets in a variety of cancers, including lung cancer, 36 and HDAC4 is a validated target of miR-1.
34,35,37 The potential therapeutic role of miR-1 also underscored that ectopic expression of miR-1 can sensitize A549 cells to the anticancer drug doxorubicin through facilitating activation of Caspase 3, Caspase 7, and PARP-1 as well as depletion of Mcl-1. 34 As for miR-486, an increase in its expression was reported in bronchioalveolar stem cells compared with control cells, 38 whereas bronchioalveolar stem cells were suggested to be the progenitor cells of lung cancer stem cells. 39 Lung cancer stem cells are believed to be the most important players in tumor development, metastasis, therapy resistance and cancer recurrence. 39, 40 Additional investigation of the regulatory mechanism of these miRNAs and their target mRNAs may improve our understanding of the molecular pathogenesis of NSCLC as well as our effectiveness in finding out potential therapy targets for NSCLC.
Our study was beneficiated from an initial genome-wide Solexa survey followed by three sets of individual qRT-PCR evaluations. The predictive effects between the relative homogeneity training and testing data sets were consistent for both individual markers and different combinations, which suggests a good internal validation (splitting samples 41 ). For the discovery data set, the performance of the four miRNAs was also comparative and served as a good external validation. We also performed a bootstrap-like cross-validation on the reliability of the risk-score procedure. These results clearly indicate that, although one particular miRNA in serum may help distinguish different subgroups, a combination of a panel of miRNAs has a great potential to offer much more sensitive and specific diagnostic tests. In different lung cancer studies of protein-coding gene expression profiles, the genes associated with patient survival can vary substantially from study to study, and few genes were consistently reported. 2, 4, [23] [24] [25] [26] [27] Therefore, the generalization of the serum miRNA signatures identified in this study warrants additional studies in different ethnic populations, preferably in prospective studies for cancer outcome surveillance as well as therapy response evaluations.
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Fig A1.
Kaplan-Meier estimates of overall survival of patients with non-small-cell lung cancer according to the four microRNAs (miRNAs) and their combinations. (A) Training set (120 patients); (B) testing set (123 patients); (C) all-combined data sets (303 patients). Labels at the top of the figure apply to all graphs in the same column.
